Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2019

View Archived Issues

Fully human stem cells show heart muscle regeneration promise

Recombinant immunotoxins achieve complete and durable tumor regression in a myeloma mouse model

Amyloid plaques age oligodendrocyte precursors

A novel more relevant model of prostate cancer

LY-3343544, a MET-ADC with potent activity in cancer models

TR1801-ADC shows high efficacy in PDX models of solid tumors

IMGC-936 demonstrates promising antitumor activity in ADAM9-expressing cancer models

Aduro BioTech discovers cyclic GMP-AMP synthase inhibitors

FORMA Therapeutics presents CREB-binding protein and histone acetyltransferase p300 inhibitors

Celldex presents a novel tetravalent human anti-CD27/PD-L1 bispecific antibody, CDX-527

New serine-protein kinase ATM inhibitors identified at AstraZeneca

Jacobio-Alpha Pharmaceuticals, Beijing Jacobio Pharmaceuticals patent FGFR-4 inhibitors

Roche and Genentech disclose complement factor D inhibitors

TQB-3804 demonstrates promising antitumor activity in EGFR-mutant tumor models

Regeneron and Alnylam collaborate to discover, develop and commercialize RNAi therapeutics

Ascentage Pharma and Junshi Bioscience to evaluate the combination of APG-1387 and toripalimab

Diarylquinoline analogues of bedaquiline with improved anti-TB potency and lower cardiotoxicity

OJT-007 and OJT-008 characterized as inhibitors of M. tuberculosis MetAP

Phase II results for benralizumab in PDGFRA-negative hypereosinophilic syndrome

FDA approves Dovato for treatment-naive HIV-1

Topline data from Japanese TIMES 1 study of imeglimin in type 2 diabetes

Poxel reports phase Ia data for MPC inhibitor PXL-065

Phase I trial assesses iC9.GD2.CAR.IL-15 T cells in pediatric relapsed or refractory neuroblastoma

Lixte Biotechnology initiates phase Ib/II study of LB-100 in MDS

Frequency Therapeutics reports phase I/II data on FX-322 for hearing restoration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...